Ginkgo Bioworks Holdings Inc. (DNA) stock soared 5.02% on Wednesday, likely boosted by positive news regarding its partner company Lucid Diagnostics.
Lucid Diagnostics, a commercial-stage cancer prevention medical diagnostics company, announced that its prospective clinical utility study for the EsoGuard® Esophageal DNA Test has been accepted for publication in the peer-reviewed journal Medicina.
The EsoGuard test is designed to detect esophageal precancer and cancer through early detection in at-risk patients. The clinical study demonstrated outstanding clinical utility, including an exceptionally high 85% patient compliance with referral to confirmatory upper endoscopy following EsoGuard testing in a real-world clinical setting.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。